The Effect of Medication Therapy Combined with Transcranial Direct Current Stimulation on Depression and Response Inhibition of Patients with Bipolar Disorder Type I

A. Pamaz Mardani  
Zanjan University of Medical Sciences

Saba Hassanvandi  
Alzahra University

Mohsen Dadashi  
Zanjan University of Medical Sciences

Ahmad Zolghadriha  
Zanjan University of Medical Sciences

Hossein Javadani  
Qazvin University of Medical Sciences

Seyedeh Elnaz Mousavi  
Shahid Beheshti University of Medical Sciences

Research Article

Keywords: Bipolar Disorder, Transcranial Direct Current Stimulation, medication, Depression, Response inhibition

DOI: https://doi.org/10.21203/rs.3.rs-519087/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective

Bipolar Disorder (BD) is one of the most common mental disorders associated with depressive symptoms and impairment in executive functions such as response inhibition. This study aimed to investigate the effectiveness of medication therapy combined with Transcranial Direct Current Stimulation (tDCS) on depression and response inhibition of patients with BD.

Method

This is a clinical trial with pretest, posttest, and follow-up design. Participants were 30 patients with BD randomly assigned to two groups of Medication + tDCS (n = 15, receiving medications plus tDCS with 2 mA intensity over dorsolateral prefrontal cortex for 10 days, two sessions per day each for 20 min) and Medaction (n = 15, receiving mood stabilizers including 300 mg lithium, 200 mg sodium valproate, and 200 mg carbamazepine two times per day). Pretest, posttest and 3-month follow-up assessments were the 21-item Hamilton Depression Rating Scale (HDRS) and a go/no-go test. Collected data were analyzed in SPSS v.20 software.

Results

The mean HDRS score in both groups was reduced after both interventional techniques, where the group received combined therapy showed more reduction (P < 0.01), although their effects were not maintained after 3 months. In examining response inhibition variable, only the combined therapy could reduce the commission error of patients under a go/no-go task (p < 0.05), but its effect was not stable; there was no significant difference in the group received medication therapy alone.

Conclusion

Medication in combination with tDCS can reduce the depressive symptoms and improve the response inhibition ability of people with BD.

1. Introduction

Bipolar Disorder (BD) is a common psychological disorder that affects about 1–5% of the total population. It is associated with significant impairment in work, family, and social life. General symptoms of BD are mood disturbances and emotional dysregulation which can lead to impairment in mood stability, executive functioning, and etc. There are two main types of bipolar disorders: bipolar I and bipolar II. According to the Diagnostic and Statistical Manual of Mental Disorders-Fifth edition (DSM-5), bipolar I disorder involves episodes of severe mania and often depression. During a manic episode, elevated mood can manifest itself as either euphoria or as irritability. People in manic episodes may spend more money or pursue unrealistic plans. Depressive episodes in bipolar disorder are similar to regular clinical depression, with depressed mood, loss of pleasure, low energy and activity, feelings of
guilt or worthlessness, and thoughts of suicide. Bipolar II disorder involves a less severe form of mania called hypomania. Epidemiological studies have reported a prevalence of 0.6% for bipolar I and 0.4% for bipolar II in the world (5), while in Iran it is 0.04% for bipolar I and 0.3% for bipolar II (6). There is evidence of cognitive impairment in BD patients (7–11). One of the most important cognitive processes that can be impaired in BD patients is response inhibition or inhibitory control (12). It is an ability that helps a person to stop and think before acting and decide when to respond. It is the ability to inhibit or control impulsive (or automatic) responses, and create responses by using attention and reasoning.

Different methods have been used to treat BD. One of these methods is drug therapy; however, with the onset of symptoms and recurrence of the disorder, patients may need hospital admission and then begin a new cycle of the medication process (13). Side effects, patients’ resistance to medication, and restrictions on medication use in some patients are among the disadvantages of medication. Therefore, there is a need for a safe and more effective method with fewer side effects (14). Recent technological advances in non-invasive brain stimulation have opened new perspectives in the treatment of psychiatric disorders. One of these methods is transcranial Direct Current Stimulation (tDCS). As a non-invasive technique of neuromodulation, it can modulate the cortical excitability by applying a weak electrical current (2 mA) over the scalp through two electrode surfaces (one anode and one cathode). Anodal tDCS causes a depolarization of neurons and thus increases cortical excitability, while cathodal tDCS causes neuronal hyperpolarization and reduces cortical excitability (15, 16). Studies have shown that tDCS is effective in treating major depressive disorder (17) and response inhibition (18, 19). The use of tDCS can be a good treatment option for patients who experience many side effects after taking medications or for patients who are resistant to medication treatment (20). To our knowledge, no clinical trial has examined the effectiveness of tDCS combined with medication in improvement of cognitive and psychological disorders in BD patients. In this regard, this study aimed to evaluate the effect of tDCS combined with medication on depression and response inhibition of patients with BD.

2. Methodology

2.1. Participants

This study is a clinical trial with a pretest, posttest, and follow-up design. The study population consists of all outpatients with BD type I referred to Sohravardi Clinic at Shahid Beheshti Hospital in Zanjan, Iran. The ethics committee of the Zanjan University of Medical Sciences (ZUMS) approved the clinical trial of this study (Approval ID: IR.ZUMS.REC.1398.452). The trial was registered at the Iranian Registry of Clinical Trials (registration No. RCTID: IRCT20191229045931N1). Of these, 30 were selected by using a purposive sampling method and based on inclusion criteria (willingness to participate, having bipolar type I diagnosed by a psychiatrist, age 18–50 years, at least a middle school education, no severe psychiatric disorders such as psychotic disorders and cognitive impairment, no history of epileptic seizures and head injuries, no substance and alcohol use, and receiving no psychological and technological intervention at least one month before study). Absence from more than two intervention sessions, suicidal ideation, need for electroconvulsive therapy during the intervention, unwillingness to
continue participation, presence of metal or electrical device in the head, and pregnancy were the criteria for exclusion from the study. Participants were randomly assigned into two groups of medication (n = 15) and medication + tDCS (n = 15).

2.2. Measures

After obtaining written informed consent from the patients for participating in the study, their demographic data (age, gender, education, marital status) were recorded. Then, they completed the 21-item Hamilton Depression Rating Scale (HDRS) and underwent Go/No-Go test. The HDRS, developed by Hamilton (21), was used to assess the severity of depressive symptoms in patients by a clinical interview. The items of HDRS are scored from 0–2 or 0–4 measuring depressed mood, feelings of guilt, suicide, initial insomnia, insomnia during the night, delayed insomnia, work and interests, retardation, agitation, psychiatric anxiety, somatic anxiety, gastrointestinal somatic symptoms, general somatic symptoms, genital symptoms, hypochondriasis, weight loss, and insight. A total score of 0–7 is considered normal, while scores of 20 or higher indicate severe depression. Its sensitivity and specificity in diagnosing positive cases of depression are 86% and 92%, respectively (22). For its Persian version, the validity through evaluating its correlation with Beck Depression Inventory and Dysfunctional Attitude Scale has been reported r = 0.55 and r = 0.39, respectively, with reported inter-rater reliability of 0.95 (23).

The Go/No-Go test was used to assess response inhibition/ inhibitory control of patients. To perform this computerized test, pairs of rectangles (white/green and white/yellow) appeared randomly on the screen for a short time. If one of these pairs was yellow, the patient was asked to make no response, but if one of them was green, s/he was asked to give one of the two following responses: If the green rectangle was on the right and the white rectangle on the left, press the keyboard button “/” rapidly, but if the white rectangle was on the right and the green rectangle on the left, press the “z” button rapidly. In the end, their commission error rate, omission error rate, inhibition, and response time (ms) were recorded. Fewer errors indicate a better response.

2.3. Intervention

Afterwards, the first group received medication (mood stabilizers including 300 mg lithium, 200 mg sodium valproate, and 200 mg carbamazepine, two times per day), while the second groups received both drug therapy and tDCS intervention. The tDCS (2 mA) was performed for 10 consecutive days, two sessions per day each for 20 minutes. To do so, two electrodes (positive anode and negative cathode) covered by a sponge soaked in saline were positioned in the subjects’ head over dorsolateral prefrontal cortex (DLPFC) with anode position over F3 and cathode over F4 according to the EEG 10–20 International System. Immediately and 3 months after the intervention, patients completed HDRS questionnaire and performed Go/No-Go test again.

2.4. Data analysis

Collected data were analyzed in SPSS v.20 using descriptive statistics (frequency, percentage, mean, standard deviation), and statistical tests including ANCOVA, multivariate and univariate ANOVA,
independent t-test, and chi-square test. Before conducting these tests, the normality of data distribution was reported by Kolmogorov-Smirnov test (p > 0.05) and the equality of variances was reported by Levene's test (p > 0.05).

3. Results

Table 1 presents the descriptive statistics for the demographic characteristics of participants. Of 30 participants, 10 were male and 5 females in the medication group where most of them were single with a high school diploma (mean age = 30.33 ± 8.63 years) and 3 male and 12 females in the medication + tDCS group where most of them were married with a high school diploma (mean age = 32.06 ± 9.43 years). At baseline, independent t-test results showed no significant difference between the two groups in terms of age (P > 0.05), while chi-square test indicated a statistically significant difference in terms of gender (p < 0.05), but not in terms of educational level and marital status (Table 1).

The mean HDRS scores of patients at three measurement stages are presented in Table 2. As can be seen from Table 2, the depression of BD patients in both groups was reduced after both interventional techniques; the group received both drug therapy and tDCS showed more reduction (21.40 ± 8.10 vs. 1.80 ± 2.21) than the group received medication alone (15.60 ± 11.28 vs. 13.53 ± 22.02). In both groups, the decrease continued slightly in the follow-up period. According to ANCOVA results shown in Table 3, after controlling covariate (pretest score), this difference between groups was statistically significant (F(1, 27) = 50.2, p = 0.000 < 0.05) and it can be said that the combination of medication with tDCS had a higher impact on the depression of BD patients than medication alone. The obtained effect size ($\eta^2$) indicated that 65% of the changes in the groups were due to the effect of the combined intervention. To measure the effect of the time factor, within-subject comparison by using repeated-measures ANOVA was conducted (Table 4). The results revealed an overall significant difference between the means at three different time points of pretest, posttest, and follow-up (p = 0.000 < 0.05). Pairwise comparison using Bonferroni test (Table 5) showed that, in combined therapy group, there was a significant difference between pretest and posttest depression scores (p = 0.000), and between pretest and follow-up depression scores (p = 0.000), but no significant differences between posttest and follow-up (p > 0.05).

Regarding the mean scores of patients under Go/No-Go test shown in Table 2, it can be seen that when we used medication alone, their errors and average response time increased, while the combination of medication with tDCS method reduced their errors and average response time to stimuli. After controlling covariate (pretest response time), the ANCOVA results presented in Table 6 showed a significant difference between groups only in terms of commission error (F = 5.36, Sig.=0.02 < 0.05) which indicates that the combination of medication with tDCS could improve the response inhibition of BD patients compared to when only medication was used. However, within-subject comparison (Table 7) showed no overall significant difference between the mean scores at three different time points of pretest, posttest, and follow-up (p > 0.05).
| Demographic factors          | Medication (n = 15) | Medication + tDCS (n = 15) | P-value* |
|-----------------------------|---------------------|----------------------------|----------|
|                             | N       | %      | N      | %      |          |
| Gender                      |         |        |        |        |          |
| Male                        | 10      | 66.7   | 3      | 20     | 0.01     |
| Female                      | 5       | 33.3   | 12     | 80     |          |
| Marital status              |         |        |        |        |          |
| Married                     | 7       | 46.7   | 8      | 53.3   | 0.71     |
| Single                      | 8       | 53.3   | 7      | 46.7   |          |
| Educational level           |         |        |        |        |          |
| Lower than high school      | 2       | 13     | 2      | 13.3   | 0.90     |
| High school diploma         | 9       | 60     | 10     | 66.7   |          |
| Bachelor's degree           | 4       | 26.7   | 3      | 20     |          |
|                             | Mean    | SD     | Mean   | SD     | P-value**|
| Age                         | 30.33   | 8.63   | 32.06  | 9.43   | 0.60     |

* Chi-square test; ** independent t-test
Table 2
Mean scores of participants in HDRS and Go/No-Go test

| Variables          | Stage   | Groups                                |
|--------------------|---------|---------------------------------------|
|                    |         | Drug therapy,                          |
|                    |         | Medication + tDCS,                     |
|                    |         | Mean ± SD                              |
|                    |         | Mean ± SD                              |
| Depression         | Pretest | 15.60 ± 11.28                          |
|                    |         | 21.40 ± 8.10                           |
|                    | Posttest| 13.53 ± 22.02                          |
|                    |         | 1.80 ± 2.21                            |
|                    | Follow-up| 11.93 ± 8.38                          |
|                    |         | 1.46 ± 2.32                            |
| Commission error   | Pretest | 1.86 ± 2.58                            |
|                    |         | 2.26 ± 1.98                            |
|                    | Posttest| 2.46 ± 3.46                            |
|                    |         | 0.73 ± 1.27                            |
|                    | Follow-up| 1.46 ± 3.54                           |
|                    |         | 0.93 ± 1.57                            |
| Omission error     | Pretest | 0.33 ± 0.72                            |
|                    |         | 3.46 ± 7.98                            |
|                    | Posttest| 3.06 ± 8.09                            |
|                    |         | 0.06 ± 0.25                            |
|                    | Follow-up| 1.60 ± 5.92                           |
|                    |         | 1.53 ± 5.93                            |
| Average response time (ms) | Pretest | 369.46 ± 46.06                         |
|                    |         | 405.40 ± 111.29                        |
|                    | Posttest| 387.33 ± 78.60                         |
|                    |         | 370.53 ± 70.27                         |
|                    | Follow-up| 373.20 ± 60.86                        |
|                    |         | 382.20 ± 73.86                         |

SD = standard deviation

Table 3
Test of between-subject effects (dependent variable: posttest depression)

| Source            | Sum of Squares | df | Mean Square | F    | Sig.  | Partial Eta squared |
|-------------------|----------------|----|-------------|------|-------|---------------------|
| Corrected model   | 1794.25        | 2  | 874.62      | 29.54| 0.000 | 0.68                |
| Intercept         | 21.68          | 1  | 21.68       | 0.73 | 0.400 | 0.02                |
| Pretest depression| 716.71         | 1  | 716.71      | 24.20| 0.000 | 0.47                |
| Group             | 1486.45        | 1  | 1486.45     | 50.20| 0.000 | 0.65                |
| Error             | 799.41         | 27 | 29.60       | -    | -     | -                   |
| Total             | 4312           | 30 | -           | -    | -     | -                   |
Table 4
Test of within-subject effects for depression variable (Greenhouse-Geisser test)

| Source         | Sum of Squares | df | Mean Square | F     | Sig. | Partial Eta squared |
|----------------|----------------|----|-------------|-------|------|---------------------|
| Depression     | 2575.35        | 1.55 | 1658.59    | 62.34 | 0.000 | 0.69                |
| Depression * Group | 1434.06    | 1.55 | 923.57     | 34.71 | 0.000 | 0.55                |
| Error          | 1156.57        | 43.47 | 26.602     | -     | -     | -                   |

Table 5
Pairwise comparison for the depression variable

| Group          | (I) time | (J) time | Mean difference (I-J) | Std. error | Sig. | 95% CI | Lower bound | Upper bound |
|----------------|----------|----------|-----------------------|------------|------|--------|-------------|-------------|
| tDCS + medication | Pretest  | Posttest | 19.60*                | 1.93       | 0.000 | 14.33  | 24.87       |
|                 | Follow- up|          | 19.93*               | 1.93       | 0.000 | 14.67  | 25.18       |
| Posttest        | Pretest  | -19.60*  | 1.93                  | 0.000      | -24.87 | -14.33 |
|                 | Follow- up|          | 0.33                  | 0.31       | 0.940  | -0.53  | 1.20        |
| Follow-up       | Pretest  | -19.93*  | 1.93                  | 0.000      | -25.18 | -14.67 |
|                 | Posttest | -0.33    | 0.31                  | 0.940      | -1.20  | 0.53   |
| medication      | Pretest  | Posttest | 2.06                  | 1.75       | 0.774  | -2.69  | 6.82        |
|                 | Follow- up|          | 3.66                  | 1.84       | 0.200  | -1.34  | 8.67        |
| Posttest        | Pretest  | -2.06    | 1.75                  | 0.774      | -6.83  | 2.69   |
|                 | Follow- up|          | 1.60                  | 1.56       | 0.974  | -2.66  | 5.86        |
| Follow-up       | Pretest  | -3.66    | 1.84                  | 0.200      | -8.67  | 1.34   |
|                 | Posttest | -1.60    | 1.56                  | 0.974      | -5.86  | 2.66   |

*The mean difference is significant at p < 0.05*
Table 6
Test of between-subject effects for the Go/No-Go test dimensions

| Source                | Dependent variable | Sum of Squares | df | Mean Square | F    | Sig. | Partial Eta squared |
|-----------------------|--------------------|----------------|----|-------------|------|------|---------------------|
| Corrected model       | Commission error   | 108.28         | 5  | 21.65       | 4.95 | 0.00 | 0.50                |
|                       | Omission error     | 82.15          | 5  | 16.43       | 0.43 | 0.81 | 0.08                |
|                       | Average response   | 62919.51       | 5  | 12583.90    | 3.18 | 0.02 | 0.39                |
|                       | time (ms)          |                |    |             |      |      |                     |
| Intercept             | Commission error   | 7.35           | 1  | 7.35        | 1.68 | 0.20 | 0.06                |
|                       | Omission error     | 6.41           | 1  | 6.41        | 0.17 | 0.68 | 0.00                |
|                       | Average response   | 13824.83       | 1  | 13824.83    | 3.49 | 0.07 | 0.12                |
|                       | time (ms)          |                |    |             |      |      |                     |
| Pretest (response time)| Commission error   | 0.74           | 1  | 0.74        | 0.17 | 0.68 | 0.00                |
|                       | Omission error     | 6.27           | 1  | 6.27        | 0.16 | 0.68 | 0.00                |
|                       | Average response   | 52031.53       | 1  | 52031.53    | 13.16| 0.00 | 0.35                |
|                       | time (ms)          |                |    |             |      |      |                     |
| Group                 | Commission error   | 23.45          | 1  | 23.45       | 5.36 | 0.02 | 0.18                |
|                       | Omission error     | 63.30          | 1  | 63.30       | 1.68 | 0.20 | 0.06                |
|                       | Average response   | 3292.17        | 1  | 3292.17     | 0.83 | 0.37 | 0.03                |
|                       | time (ms)          |                |    |             |      |      |                     |
| Error                 | Commission error   | 104.91         | 24 | 4.37        |      |      |                     |
|                       | Omission error     | 903.21         | 24 | 37.63       |      |      |                     |
|                       | Average response   | 94844.35       | 24 | 3951.84     |      |      |                     |
|                       | time (ms)          |                |    |             |      |      |                     |
| Total                 | Commission error   | 290            | 30 |             |      |      |                     |
|                       | Omission error     | 1059           | 30 |             |      |      |                     |
|                       | Average response   | 4465478        | 30 |             |      |      |                     |
|                       | time (ms)          |                |    |             |      |      |                     |
Discussion

TDCS is a non-invasive brain stimulation technique that modulates cortical excitability and spontaneous brain activity in a safe, economic, and well-tolerated manner. Since BD is a common and complicated disorder that sometimes causes long-term use of psychiatric medications, the use of new alternative therapies such as TDCS can be effective in improving the performance of BD patients. To the best of our knowledge, this is the first clinical trial that investigates the effect of tDCS combined with medication therapy on depression and inhibitory control of patients with BD. The findings of our study revealed the effectiveness of right anode/left cathode tDCS (2 mA, 20 min) combined with medication in reducing depression of adults with BD compared to those received medication only. Some studies have examined the effect of tDCS on the depression of BD patients. In a clinical trial by Sampaio-Junior et al. (24), patients with bipolar depression received left prefrontal anodal stimulation as an add-on treatment to their pharmacological therapy. Patients receiving active stimulation had a more significant symptom reduction as compared to those treated with sham tDCS. Dondé et al. (25) in a meta-analysis showed that tDCS could improve depressive symptoms in patients with bipolar depression, particularly after 1 week of treatment. Herrera-Melendez et al. (26) in a review study also found out that tDCS potentially improves depressive symptoms in patients with bipolar depression. Aparicio et al. (27) and Martin et al. (28) also concluded that tDCS can reduce depressive symptoms. McClintock et al. (29), in a controlled clinical trial, concluded that tDCS could have positive neurocognitive effects in patients with unipolar and bipolar depression. There is one published case report on the combination of tDCS with pharmacological treatment in a male patient with an acute episode of mania (30) where the authors performed anodal
tDCS over the right DLPFC combined with a pharmacological intervention and reported an improvement of manic symptoms that lasted until 72 h after stimulation. These findings are consistent with our results. In our study, the use of medication alone (mood stabilizers) also reduced depression of BD patients which is consistent with the results of Sachs et al. (31), Pacchiarotti et al. (32), who reported the effect of antidepressant drugs in BD.

DLPFC has been linked to depression due to decreased left DLPFC performance and increased right DLPFC performance (33). During the depression, there is a possibility of dysfunction along with decreased regional blood flow or glucose metabolism in left DLPFC (34) and hyperactivity of the right DLPFC (according to the theory of prefrontal asymmetry). The right anode/left cathode tDCS can therefore help reduce depressive symptoms (33). On the other hand, although mood stabilizers have been approved by the FDA for treating patients with BD, they are not enough because some patients are resistant to these medications or high doses of these medications can reduce the patients’ daily performance. The use of tDCS can facilitate the effects of medication therapy. It can modulate synaptic transmission by regulating the dose of transmitters, including serotonin (35). Hence, it is suggested that tDCS can be a useful method for treating depression of BD patients combined with medication. The effect of combined therapy in our study was not stable for 3 months after stimulation. This may be because of the low number of sessions and duration (10 sessions each for 20 min). The use of high number and longer sessions may affect the stability of its effect.

The findings of our study showed the effectiveness of combining tDCS with medication in reducing commission error of BD patients under a go/no-go task compared to the medication therapy alone, indicating its impact on the improvement of their response inhibition ability. Some studies have reported the effect of tDCS on inhibitory control such as Hogeveen eta al. (18), Cunillera et al. (36), and Wynn et al. (37), indicating that the placement of electrodes in different areas of the brain causes different efficiencies over time. For justifying the results, it can be said that the frontal-lateral region, as one of the important regions of the prefrontal cortex which was simulated in our study, is responsible for identifying and determining actions, evaluating and predicting the consequences of current behavior, social control, and response inhibition. Moreover, based on the Barkley’s inhibition model, it is assumed that the proper executive functioning depends on the proper functioning of inhibition in the frontal and prefrontal cortex (38). Furthermore, it has been reported that the F3 region in the prefrontal cortex plays an important role in inhibiting inappropriate behavioral responses(39). Therefore, stimulation of this area could improve the management of impulsive behaviors and response inhibition in BD patients by regulating the activity of frontal, prefrontal lobes, and anterior cingulate cortex. As mentioned above, tDCS modulates synaptic transmission by regulating the dose of transmitters. Hence, it can be said that TDCS is a complementary therapy and can accelerate and improve the mechanism of medication therapy.

In our study, gains in response inhibition ability were not maintained at 3-month follow-up. Stable results may be achieved if the number and duration of tDCS sessions increases or the stimulated area is changed. Since BD is one of the most severe psychiatric disorders and, on the other hand, response inhibition is severely impaired in these patients and is associated with other behavioral consequences,
other interventions such as emotion regulation strategies, cognitive rehabilitation are required along with tDCS to be able to stabilize this effectiveness. Medication therapy alone (use of mood stabilizers) did not improve response inhibition ability of patients in our study. This is consistent with the results of Pavuluri et al. (40) who showed that treatment with either risperidone or divalproex failed to dampen disordered amygdala connectivity in the occipital-limbic network during a response inhibition fMRI task, but is against the results of Pavuluri et al. (41) who showed that treatment with second-generation antipsychotics followed by lamotrigine monotherapy enhanced prefrontal and temporal lobe activity during a go/no-go task.

Some of the limitations of the present study were the use of a purposive sampling method, small sample size, and not examining different TDCS protocols. Therefore, it is suggested that further studies be performed using a larger sample size and objective tools such as electroencephalography and functional magnetic resonance imaging. Moreover, it is recommended that the effect of combining medication therapy with other novel therapies such as neurofeedback or repetitive transcranial magnetic stimulation be investigated.

**Conclusion**

Combination of tDCS with medication can significantly reduce depressive symptoms and improve response inhibition ability of adults with BD in a short-term period.

**Abbreviations**

**BD:** bipolar disorder

**TDCS:** transcranial direct current stimulation

**DLPFC:** Dorsolateral Prefrontal Cortex

**Declarations**

**Ethics approval and consent to participate**

Ethical approval from the Research Ethics Committee of Zanjan University of Medical Sciences (Code: IR.ZUMS.REC.1398.452) and written informed consent from the patients for participating in the study was received.

**Consent for publication**

Not applicable,

**Availability of data and materials**
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors of this paper report no conflicts of interest in connection with this manuscript.

**Funding source**

This study was financially supported by the Zanjan University of Medical Sciences.

**Authors' contributions**

All authors made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data. Authors SEM and MD designed the experiment. Authors PD, AZ and HJ acquired the data. Authors SEM, PM and MD analyzed the data. Authors SEM, PM and SH undertook the literature searches and wrote the first draft of the manuscript. All authors contributed to and revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This study obtained its ethical approval from the Research Ethics Committee of Zanjan University of Medical Sciences (Code: IR.ZUMS.REC.1398.452) and is clinical trial registred by Iranian Registry of Clinical Trials (code: IRCT20191229045931N1). The authors would like to thank all the patients participated in this study for their cooperation.

**References**

1. Dome P, Rihmer Z, Gonda X. Suicide risk in bipolar disorder: a brief review. Medicina. 2019;55(8):403.
2. Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos J. Functioning and disability in bipolar disorder: an extensive review. Psychotherapy and psychosomatics. 2009;78(5):285–97.
3. Green MJ, Cahill CM, Malhi GS. The cognitive and neurophysiological basis of emotion dysregulation in bipolar disorder. Journal of affective disorders. 2007;103(1–3):29–42.
4. Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®): American Psychiatric Pub; 2013.
5. Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Therapeutic advances in psychopharmacology. 2018;8(9):251–69.
6. Pouretemad HR, Naghavi HR, Malekafzali H, Noorbala AA, Davidian H, Ghanizadeh A, et al. Prevalence of mood disorders in Iran. Iranian Journal of Psychiatry. 2006:59–64.
7. Solé B, Jiménez E, Torrent C, Reinares M, Bonnin CdM, Torres I, et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. International Journal of Neuropsychopharmacology.
8. Elias LR, Miskowiak KW, Vale AM, Köhler CA, Kjærstad HL, Stubbs B, et al. Cognitive impairment in euthymic pediatric bipolar disorder: a systematic review and meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry. 2017;56(4):286–96.

9. Miskowiak KW, Burdick K, Martinez-Aran A, Bonnin C, Bowie C, Carvalho A, et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar disorders. 2018;20(3):184–94.

10. Tucker JD, Bertke AS. Assessment of cognitive impairment in HSV-1 positive schizophrenia and bipolar patients: systematic review and meta-analysis. Schizophrenia Research. 2019;209:40–7.

11. Srivastava C, Bhardwaj A, Sharma M, Kumar S. Cognitive deficits in euthymic patients with bipolar disorder: State or trait marker? The Journal of Nervous and Mental Disease. 2019;207(2):100–5.

12. Leibenluft E, Rich BA, Vinton DT, Nelson EE, Fromm SJ, Berghorst LH, et al. Neural circuitry engaged during unsuccessful motor inhibition in pediatric bipolar disorder. American Journal of Psychiatry. 2007;164(1):52–60.

13. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Archives of General Psychiatry. 1990;47(7):665–71.

14. Asbaghi E, Rafieinia P, Hosseini SM, Sabahi P. The effectiveness of rTMS on working memory and symptoms of bipolar disorder. 2017.

15. Bai Y, Xia X, Kang J, Yang Y, He J, Li X. TDCS modulates cortical excitability in patients with disorders of consciousness. NeuroImage: Clinical. 2017;15:702–9.

16. Varoli E, Pisoni A, Mattavelli GC, Vergallito A, Gallucci A, Mauro LD, et al. Tracking the effect of cathodal transcranial direct current stimulation on cortical excitability and connectivity by means of TMS-EEG. Frontiers in neuroscience. 2018;12:319.

17. Taremian F, Nazari S, Moradveisi L, Moloodi R. Transcranial direct current stimulation on opium craving, depression, and anxiety: a preliminary study. The journal of ECT. 2019;35(3):201–6.

18. Hogeveen J, Grafman J, Aboseria M, David A, Bikson M, Hauner K. Effects of high-definition and conventional tDCS on response inhibition. Brain stimulation. 2016;9(5):720–9.

19. Nieratschker V, Kiefer C, Giel K, Krüger R, Plewnia C. The COMT Val/Met polymorphism modulates effects of tDCS on response inhibition. Brain stimulation. 2015;8(2):283–8.

20. Mondino M, Bennabi D, Poulet E, Galvao F, Brunelin J, Haffen E. Can transcranial direct current stimulation (tDCS) alleviate symptoms and improve cognition in psychiatric disorders? The World Journal of Biological Psychiatry. 2014;15(4):261–75.

21. Hamilton M. A rating scale for depression J Neurol Neurosurg Psychiatry 23: 56–62. View Article. 1960.

22. Strik JJ, Honig A, Lousberg R, Denollet J. Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. Psychosomatics.
23. Ebrahimi A, Neshatdoost HT, Mousavi SG, Asadollahi GA, Nasiri H. Controlled randomized clinical trial of spirituality integrated psychotherapy, cognitive-behavioral therapy and medication intervention on depressive symptoms and dysfunctional attitudes in patients with dysthymic disorder. Advanced biomedical research. 2013;2.

24. Sampaio-Junior B, Tortella G, Borrione L, Moffa AH, Machado-Vieira R, Cretaz E, et al. Efficacy and safety of transcranial direct current stimulation as an add-on treatment for bipolar depression: a randomized clinical trial. JAMA psychiatry. 2018;75(2):158–66.

25. Dondé C, Amad A, Nieto I, Brunoni AR, Neufeld NH, Bellivier F, et al. Transcranial direct-current stimulation (tDCS) for bipolar depression: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2017;78:123–31.

26. Herrera-Melendez A-L, Bajbouj M, Aust S. Application of transcranial direct current stimulation in psychiatry. Neuropsychobiology. 2019:1–12.

27. Aparicio LV, Rosa V, Razza LM, Sampaio-Junior B, Borrione L, Valiengo L, et al. Transcranial direct current stimulation (tDCS) for preventing major depressive disorder relapse: Results of a 6-month follow-up. Depression and anxiety. 2019;36(3):262–8.

28. Martin DM, Moffa A, Nikolin S, Bennabi D, Brunoni AR, Flannery W, et al. Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: an individual patient data meta-analysis of randomised, sham-controlled trials. Neuroscience & Biobehavioral Reviews. 2018;90:137–45.

29. McClintock SM, Martin DM, Lisanby SH, Alonzo A, McDonald WM, Aaronson ST, et al. Neurocognitive effects of transcranial direct current stimulation (tDCS) in unipolar and bipolar depression: Findings from an international randomized controlled trial. Depression and anxiety. 2020;37(3):261–72.

30. Schestatsky P, Janovik N, Lobato MI, Belmonte-de-Abreu P, Schestatsky S, Shiozawa P, et al. Rapid therapeutic response to anodal tDCS of right dorsolateral prefrontal cortex in acute mania. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. 2013;6(4):701–3.

31. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine. 2007;356(17):1711–22.

32. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry. 2013;170(11):1249–62.

33. Brunoni A, Nitsche M, Loo C. Transcranial direct current stimulation in neuropsychiatric disorders. Cham, CH: Springer International Publishing. 2016.

34. Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. The British Journal of Psychiatry. 2016;208(6):522–31.
35. Kuo H-I, Paulus W, Batsikadze G, Jamil A, Kuo M-F, Nitsche MA. Chronic enhancement of serotonin facilitates excitatory transcranial direct current stimulation-induced neuroplasticity. Neuropsychopharmacology. 2016;41(5):1223–30.

36. Cunillera T, Brignani D, Cucurell D, Fuentemilla L, Miniussi C. The right inferior frontal cortex in response inhibition: A tDCS–ERP co-registration study. Neuroimage. 2016;140:66–75.

37. Wynn SC, Driessen JM, Glennon JC, Brazil IA, Schutter DJ. Cerebellar transcranial direct current stimulation improves reactive response inhibition in healthy volunteers. The Cerebellum. 2019;18(6):983–8.

38. Barkley RA, Murphy KR. Attention-deficit hyperactivity disorder: A clinical workbook: Guilford Press; 2006.

39. Yun GJ, Chun MH, Kim BR. The effects of transcranial direct-current stimulation on cognition in stroke patients. Journal of stroke. 2015;17(3):354.

40. Pavuluri MN, Ellis JA, Wegbreit E, Passarotti AM, Stevens MC. Pharmacotherapy impacts functional connectivity among affective circuits during response inhibition in pediatric mania. Behavioural brain research. 2012;226(2):493–503.

41. Pavuluri MN, Passarotti AM, Harral EM, Sweeney JA. Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder. The Journal of clinical psychiatry. 2010;71(11):1526.